Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gert J Ossenkoppele

Showing results (131-140 of 193) with videos related to

Pageof 20
Sort By:
Leukemia|January 25, 2024
Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemiaJesse M Tettero, Maaike E Heidinga, Tim R Mocking, et al.
Cancer Medicine|December 25, 2021
The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzedKaterina Bakunina, Hein Putter, Jurjen Versluis, et al.
The New England Journal of Medicine|March 18, 2011
Cytarabine dose for acute myeloid leukemiaBob Löwenberg, Thomas Pabst, Edo Vellenga, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2013
Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)Noortje Thielen, Bronno van der Holt, Jan J Cornelissen, et al.
Blood|December 4, 2004
Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomasJettie J F Muris, Saskia A G M Cillessen, Wim Vos, et al.
Annals of Hematology|March 11, 2021
Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohortMagdalena M Brune, Georg Stüssi, Pontus Lundberg, et al.
Blood|November 3, 2009
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetHartmut Döhner, Elihu H Estey, Sergio Amadori, et al.
Blood|April 9, 2004
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patientsGert J Ossenkoppele, Wilfried J Graveland, Pieter Sonneveld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2022
Prognostic Value of <i>FLT3</i>-Internal Tandem Duplication Residual Disease in Acute Myeloid LeukemiaTim Grob, Mathijs A Sanders, Christian M Vonk, et al.
British Journal of Haematology|February 28, 2009
Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survivalYuri Souwer, Martine E D Chamuleau, Arjan A van de Loosdrecht, et al.
Pageof 20

Showing results (131-140 of 193) with videos related to

Sort By:
Pageof 20
Leukemia|January 25, 2024
Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemiaJesse M Tettero, Maaike E Heidinga, Tim R Mocking, et al.
Cancer Medicine|December 25, 2021
The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzedKaterina Bakunina, Hein Putter, Jurjen Versluis, et al.
The New England Journal of Medicine|March 18, 2011
Cytarabine dose for acute myeloid leukemiaBob Löwenberg, Thomas Pabst, Edo Vellenga, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2013
Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)Noortje Thielen, Bronno van der Holt, Jan J Cornelissen, et al.
Blood|December 4, 2004
Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomasJettie J F Muris, Saskia A G M Cillessen, Wim Vos, et al.
Annals of Hematology|March 11, 2021
Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohortMagdalena M Brune, Georg Stüssi, Pontus Lundberg, et al.
Blood|November 3, 2009
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetHartmut Döhner, Elihu H Estey, Sergio Amadori, et al.
Blood|April 9, 2004
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patientsGert J Ossenkoppele, Wilfried J Graveland, Pieter Sonneveld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2022
Prognostic Value of <i>FLT3</i>-Internal Tandem Duplication Residual Disease in Acute Myeloid LeukemiaTim Grob, Mathijs A Sanders, Christian M Vonk, et al.
British Journal of Haematology|February 28, 2009
Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA-DOA mRNA as a prognostic factor for survivalYuri Souwer, Martine E D Chamuleau, Arjan A van de Loosdrecht, et al.
Pageof 20